Omalizumab for pediatric asthma

Robert G. Townley, Swati Agrawal, Kiran Sapkota

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Importance to the field: Omalizumab is of proven efficacy in the treatment of severe allergic bronchial asthma and works through inhibiting the activity of IgE and the allergic immune mechanism IgE mediates. It has been demonstrated to be efficacious in children with asthma but is not approved by the FDA for use in children below 12 years of age. Areas covered in this review: Omalizumab is a 95% humanized monoclonal antibody that binds to circulating IgE at the same site on the Fc domain as the high-affinity IgE receptor, FcεRI. This blocks the interaction between IgE and mast cells and basophils, thereby preventing the release of inflammatory mediators that cause allergic signs and symptoms. What the reader will gain: From the review of the literatures and statements from the FDA, Genentec and Novartis, the reader will gain a better appreciation of the value of omalizumab in treatment of severe asthma and the current status of its reported side effects. Take home message: Omalizumab is of proven efficacy in adults and children with severe asthma and allows a markedly reduced dependence on oral and inhaled corticosteroids and decreased hospitalizations. A potential mechanism of omalizumab's effect on thrombus formation and cardiovascular effect is postulated.

Original languageEnglish
Pages (from-to)1595-1608
Number of pages14
JournalExpert Opinion on Biological Therapy
Volume10
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

Pediatrics
Asthma
Immunoglobulin E
Antibodies, Monoclonal, Humanized
IgE Receptors
Basophils
Mast Cells
Signs and Symptoms
Adrenal Cortex Hormones
Hospitalization
Thrombosis
Omalizumab

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Townley, R. G., Agrawal, S., & Sapkota, K. (2010). Omalizumab for pediatric asthma. Expert Opinion on Biological Therapy, 10(11), 1595-1608. https://doi.org/10.1517/14712598.2010.526103

Omalizumab for pediatric asthma. / Townley, Robert G.; Agrawal, Swati; Sapkota, Kiran.

In: Expert Opinion on Biological Therapy, Vol. 10, No. 11, 11.2010, p. 1595-1608.

Research output: Contribution to journalReview article

Townley, RG, Agrawal, S & Sapkota, K 2010, 'Omalizumab for pediatric asthma', Expert Opinion on Biological Therapy, vol. 10, no. 11, pp. 1595-1608. https://doi.org/10.1517/14712598.2010.526103
Townley, Robert G. ; Agrawal, Swati ; Sapkota, Kiran. / Omalizumab for pediatric asthma. In: Expert Opinion on Biological Therapy. 2010 ; Vol. 10, No. 11. pp. 1595-1608.
@article{83214057800e4e9183590ab2b7847081,
title = "Omalizumab for pediatric asthma",
abstract = "Importance to the field: Omalizumab is of proven efficacy in the treatment of severe allergic bronchial asthma and works through inhibiting the activity of IgE and the allergic immune mechanism IgE mediates. It has been demonstrated to be efficacious in children with asthma but is not approved by the FDA for use in children below 12 years of age. Areas covered in this review: Omalizumab is a 95{\%} humanized monoclonal antibody that binds to circulating IgE at the same site on the Fc domain as the high-affinity IgE receptor, FcεRI. This blocks the interaction between IgE and mast cells and basophils, thereby preventing the release of inflammatory mediators that cause allergic signs and symptoms. What the reader will gain: From the review of the literatures and statements from the FDA, Genentec and Novartis, the reader will gain a better appreciation of the value of omalizumab in treatment of severe asthma and the current status of its reported side effects. Take home message: Omalizumab is of proven efficacy in adults and children with severe asthma and allows a markedly reduced dependence on oral and inhaled corticosteroids and decreased hospitalizations. A potential mechanism of omalizumab's effect on thrombus formation and cardiovascular effect is postulated.",
author = "Townley, {Robert G.} and Swati Agrawal and Kiran Sapkota",
year = "2010",
month = "11",
doi = "10.1517/14712598.2010.526103",
language = "English",
volume = "10",
pages = "1595--1608",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Omalizumab for pediatric asthma

AU - Townley, Robert G.

AU - Agrawal, Swati

AU - Sapkota, Kiran

PY - 2010/11

Y1 - 2010/11

N2 - Importance to the field: Omalizumab is of proven efficacy in the treatment of severe allergic bronchial asthma and works through inhibiting the activity of IgE and the allergic immune mechanism IgE mediates. It has been demonstrated to be efficacious in children with asthma but is not approved by the FDA for use in children below 12 years of age. Areas covered in this review: Omalizumab is a 95% humanized monoclonal antibody that binds to circulating IgE at the same site on the Fc domain as the high-affinity IgE receptor, FcεRI. This blocks the interaction between IgE and mast cells and basophils, thereby preventing the release of inflammatory mediators that cause allergic signs and symptoms. What the reader will gain: From the review of the literatures and statements from the FDA, Genentec and Novartis, the reader will gain a better appreciation of the value of omalizumab in treatment of severe asthma and the current status of its reported side effects. Take home message: Omalizumab is of proven efficacy in adults and children with severe asthma and allows a markedly reduced dependence on oral and inhaled corticosteroids and decreased hospitalizations. A potential mechanism of omalizumab's effect on thrombus formation and cardiovascular effect is postulated.

AB - Importance to the field: Omalizumab is of proven efficacy in the treatment of severe allergic bronchial asthma and works through inhibiting the activity of IgE and the allergic immune mechanism IgE mediates. It has been demonstrated to be efficacious in children with asthma but is not approved by the FDA for use in children below 12 years of age. Areas covered in this review: Omalizumab is a 95% humanized monoclonal antibody that binds to circulating IgE at the same site on the Fc domain as the high-affinity IgE receptor, FcεRI. This blocks the interaction between IgE and mast cells and basophils, thereby preventing the release of inflammatory mediators that cause allergic signs and symptoms. What the reader will gain: From the review of the literatures and statements from the FDA, Genentec and Novartis, the reader will gain a better appreciation of the value of omalizumab in treatment of severe asthma and the current status of its reported side effects. Take home message: Omalizumab is of proven efficacy in adults and children with severe asthma and allows a markedly reduced dependence on oral and inhaled corticosteroids and decreased hospitalizations. A potential mechanism of omalizumab's effect on thrombus formation and cardiovascular effect is postulated.

UR - http://www.scopus.com/inward/record.url?scp=77958482558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958482558&partnerID=8YFLogxK

U2 - 10.1517/14712598.2010.526103

DO - 10.1517/14712598.2010.526103

M3 - Review article

C2 - 20955114

AN - SCOPUS:77958482558

VL - 10

SP - 1595

EP - 1608

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 11

ER -